Skip to main content

Agenus to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference

 

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, will participate in a fireside chat and investor one-on-ones at the upcoming Oppenheimer Healthcare Conference on February 13th - 14th. The fireside chat will take place at 8:00 a.m. ET on February 14th.

A live webcast and replay of the fireside chat will be accessible on the company’s website at https://investor.agenusbio.com/events-and-presentations.

About Agenus

Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  208.54
+3.27 (1.59%)
AAPL  271.99
+5.81 (2.18%)
AMD  212.67
+16.07 (8.17%)
BAC  50.38
-0.70 (-1.36%)
GOOG  311.15
-0.54 (-0.17%)
META  638.26
+1.01 (0.16%)
MSFT  388.10
+3.63 (0.94%)
NVDA  192.89
+1.34 (0.70%)
ORCL  145.52
+4.21 (2.98%)
TSLA  409.81
+9.98 (2.50%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.